394 related articles for article (PubMed ID: 26898799)
1. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
2. An mDia2/ROCK signaling axis regulates invasive egress from epithelial ovarian cancer spheroids.
Pettee KM; Dvorak KM; Nestor-Kalinoski AL; Eisenmann KM
PLoS One; 2014; 9(2):e90371. PubMed ID: 24587343
[TBL] [Abstract][Full Text] [Related]
3. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
4. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
5. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
Singh RK; Gaikwad SM; Jinager A; Chaudhury S; Maheshwari A; Ray P
Cancer Lett; 2014 Nov; 354(2):254-62. PubMed ID: 25157649
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.
Uddin S; Jehan Z; Ahmed M; Alyan A; Al-Dayel F; Hussain A; Bavi P; Al-Kuraya KS
Mol Med; 2011; 17(7-8):635-45. PubMed ID: 21442130
[TBL] [Abstract][Full Text] [Related]
7. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
[TBL] [Abstract][Full Text] [Related]
8. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
[TBL] [Abstract][Full Text] [Related]
9. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitor of formin homology 2 domains (SMIFH2) reveals the roles of the formin family of proteins in spindle assembly and asymmetric division in mouse oocytes.
Kim HC; Jo YJ; Kim NH; Namgoong S
PLoS One; 2015; 10(4):e0123438. PubMed ID: 25837661
[TBL] [Abstract][Full Text] [Related]
11. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
Rafehi S; Ramos Valdes Y; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Endocr Relat Cancer; 2016 Mar; 23(3):147-59. PubMed ID: 26647384
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Oliva P; Decio A; Castiglioni V; Bassi A; Pesenti E; Cesca M; Scanziani E; Belotti D; Giavazzi R
Br J Cancer; 2012 Jul; 107(2):360-9. PubMed ID: 22713663
[TBL] [Abstract][Full Text] [Related]
13. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
14. Differential Toxicity of mDia Formin-Directed Functional Agonists and Antagonists in Developing Zebrafish.
LeCorgne H; Tudosie AM; Lavik K; Su R; Becker KN; Moore S; Walia Y; Wisner A; Koehler D; Alberts AS; Williams FE; Eisenmann KM
Front Pharmacol; 2018; 9():340. PubMed ID: 29692731
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule agonists of mammalian Diaphanous-related (mDia) formins reveal an effective glioblastoma anti-invasion strategy.
Arden JD; Lavik KI; Rubinic KA; Chiaia N; Khuder SA; Howard MJ; Nestor-Kalinoski AL; Alberts AS; Eisenmann KM
Mol Biol Cell; 2015 Nov; 26(21):3704-18. PubMed ID: 26354425
[TBL] [Abstract][Full Text] [Related]
16. The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
Gunay G; Kirit HA; Kamatar A; Baghdasaryan O; Hamsici S; Acar H
Gynecol Oncol; 2020 Nov; 159(2):563-572. PubMed ID: 32958270
[TBL] [Abstract][Full Text] [Related]
17. Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo.
Lu X; Wang L; Mei J; Wang X; Zhu X; Zhang Q; Lv J
Biochem Biophys Res Commun; 2013 Jun; 435(3):385-90. PubMed ID: 23665331
[TBL] [Abstract][Full Text] [Related]
18. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
19. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids.
Correa RJ; Peart T; Valdes YR; DiMattia GE; Shepherd TG
Carcinogenesis; 2012 Jan; 33(1):49-58. PubMed ID: 22045027
[TBL] [Abstract][Full Text] [Related]
20. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.
Vidal A; Muñoz C; Guillén MJ; Moretó J; Puertas S; Martínez-Iniesta M; Figueras A; Padullés L; García-Rodriguez FJ; Berdiel-Acer M; Pujana MA; Salazar R; Gil-Martin M; Martí L; Ponce J; Molleví DG; Capella G; Condom E; Viñals F; Huertas D; Cuevas C; Esteller M; Avilés P; Villanueva A
Clin Cancer Res; 2012 Oct; 18(19):5399-411. PubMed ID: 22896654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]